CTY

City Therapeutics Inc

21.46

Oct 19 • 3:59 PM ET -0.94 (-4.20%)

21.64

Aftermarket • 7:30 PM ET +0.18 (0.84%)

Healthcare Biotechnology USA Small NASD

Today, 4:05 PMCity Therapeutics closes its upsized Nasdaq IPO at $18 per share, raising $230 million in gross proceeds after underwriters fully exercise their overallotment option.

Peers: ARWR SLN WVE ALNY ABUS IONS DYN BLTE KRRO PRQR

| Held by: TDNA

Index	-
Market Cap	1.08B
Enterprise Value	-
Income	-
Sales	-
Book/sh	-
Cash/sh	-
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	-
IPO	Oct 16, 2026

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	-
P/C	-
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	-
Current Ratio	-
Debt/Eq	-
LT Debt/Eq	-
Option/Short	No / Yes

EPS (ttm)	-
EPS next Y	-
EPS next Q	-
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	- -
Sales past 3/5Y	- -
EPS Y/Y TTM	-
Sales Y/Y TTM	-
EPS Q/Q	-
Sales Q/Q	-
Earnings	-
EPS/Sales Surpr.	- -

Insider Own	-
Insider Trans	-
Inst Own	11.70%
Inst Trans	-
ROA	-
ROE	-
ROIC	-
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-2.14%
SMA50	-2.14%
SMA200	-2.14%
Trades

Shs Outstand	50.33M
Shs Float	-
Short Float	-
Short Ratio	-
Short Interest	-
52W High	23.88 -10.13%
52W Low	20.50 4.68%
Volatility	- -
ATR (14)	2.37
RSI (14)	-
Beta	-
Rel Volume	0.21
Avg Volume	1.41M
Volume	302,368

Perf Week	-
Perf Month	-
Perf Quarter	-
Perf Half Y	-
Perf YTD	-6.70%
Perf Year	-
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	-
Target Price	-
Prev Close	22.40
Price	21.46
Change %	-4.20%

Today 04:01PM	City Therapeutics Announces Closing of $230.0 Million Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Oct-16-26 01:46PM	Another Biotech IPO Pops on Rough Day for Broader Market (Barrons.com)
01:39PM	City Therapeutics surges in market debut after upsizing $200M IPO (Investing.com)

City Therapeutics, Inc. operates as a clinical-stage biotechnology company. It engages in the development of RNAi therapeutics. The company was founded by John Maraganore, Sebastian Trousil, Ari Nowacek, Mark Keating, Kotaro Nakanishi, Yukihide Tomari, and Phillip Zamore on July 17, 2023 and is headquartered in Cambridge, MA.

Ph.D.Dr. John Michael Maraganore M.D.

PresidentDr. Andrew C. Orth M.B.A.

Chief Scientific OfficerDr. Tracy Zimmermann Ph.D.

Ph.D.Dr. Baisong Mei M.D.

M.D.Dr. Ari Nowacek M.B.A.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
ARCH Venture Partners XII, LLC	10% Owner	Oct 19 '26	Buy	18.00	170,000	3,060,000	13,692,507	Oct 19 05:38 PM
NELSEN ROBERT	Director	Oct 19 '26	Buy	18.00	170,000	3,060,000	13,692,507	Oct 19 05:37 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CTY

City Therapeutics Inc

Upgrade your Finviz experience